HOUSTON (AP) _ Bellicum Pharmacueticals Inc. (BLCM) on Thursday reported a loss of $29 million in its fourth quarter.
On a per-share basis, the Houston-based company said it had a loss of $5.82. Losses, adjusted for non-recurring costs, came to $2.94 per share.
The drug developer posted revenue of $5.1 million in the period.
For the year, the company reported that its loss widened to $112.5 million, or $24.01 per share. Revenue was reported as $7.1 million.
Bellicum Pharmaceuticals shares have decreased 54% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $5.91, a decrease of 82% in the last 12 months.